Composition, form of production and packaging
? Tablets are round, flat, oblique to the edge, white or almost white in color, with impregnations.
1 tab.
peppermint oil 580 mcg
Phenobarbital 7.5 mg
ethyl ОІ-bromoisovaleric acid 8.2 mg
Excipients: beta-cyclodextrin 55.55 mg, potato starch 13 mg, lactose monohydrate 43.77 mg, microcrystalline cellulose 10.5 mg, magnesium stearate 0.9 mg.
10 pieces. - packings cellular planimetric (2) - packs cardboard.
10 pieces. - packings cellular planimetric (10) - packs cardboard.
INSTRUCTION FOR THE SPECIALIST.
Description of the drug approved by the manufacturer for the printed edition of 2011.
PHARMACHOLOGIC EFFECT
Combined drug, the effect of which is due to the properties of its constituent substances. Has a sedative and spasmolytic effect. Facilitates the onset of natural sleep.
Ethyl bromizovalerianate (ethyl ester of alpha-bromizovaleric acid) has a sedative (similar to the valerian effect) and spasmolytic effect due to irritation of predominantly oral and nasopharyngeal receptors, a decrease in reflex excitability in the central parts of the nervous system, and increased inhibition in neurons of the cortex and subcortical structures of the brain, and also a decrease in the activity of the central vasomotor centers and a direct local antispasmodic effect on smooth muscle.
Phenobarbital enhances the sedative effect of other components, helps to reduce excitation of the central nervous system (CNS) and facilitates the onset of sleep.
Peppermint oil has a reflex vasodilating, spasmolytic, mild choleretic, antiseptic effect. The mechanism of action is associated with the ability to irritate the "cold" receptors of the oral mucosa and reflexively expand primarily the vessels of the heart and brain. Eliminates the phenomena of flatulence due to irritation of the receptors of the mucous membrane of the gastrointestinal tract (GIT), strengthening the peristalsis of the intestine.
INDICATIONS
Corvalol is prescribed as a symptomatic (soothing and vasodilating) remedy for functional disorders of the cardiovascular system, neurosis-like conditions, accompanied by increased irritability, with disturbed sleep, tachycardia, a state of excitation with pronounced vegetative manifestations; as an antispasmodic - for intestinal spasms.
DOSING MODE
The dose is set individually. Take in, before eating, drink with water. Adults, as a rule, appoint 1-2 tablets 2 times a day. With tachycardia, a single dose can be increased to 3 tablets. The maximum daily dose is 6 tablets.
Duration of the drug is determined by the doctor individually.
SIDE EFFECT
Drowsiness, dizziness, slow heart rate, decreased ability to concentrate, allergic reactions. There may be violations from the gastrointestinal tract. These phenomena occur with a decrease in the dose of the drug or discontinuation of the drug.
With prolonged use of the drug, there may be a drug dependence, addiction, the "withdrawal" syndrome, as well as the accumulation of bromine in the body and the development of bromism phenomena.
CONTRAINDICATIONS
Hypersensitivity to the components of the drug; expressed violations of kidney and / or liver function, lactation period (if breastfeeding is necessary, breastfeeding should be addressed), pregnancy, age 18 years (efficacy and safety not established), lactose deficiency, lactose intolerance, glucose- galactose malabsorption (the preparation contains lactose).
PREGNANCY AND LACTATION
Contraindicated in pregnancy and during breastfeeding.
APPLICATION FOR FUNCTIONS OF THE LIVER
Contraindicated in severe impairment of kidney function.
APPLICATION FOR VIOLATIONS OF THE FUNCTION OF KIDNEYS
Contraindicated in severe violations of liver function.
APPLICATION FOR CHILDREN
The experience of using the drug in children under 18 years is absent.
SPECIAL INSTRUCTIONS
The experience of using the drug in children under 18 years is absent.
During the use of the drug should not drink alcohol.
It is recommended to refrain from engaging in potentially dangerous activities that require a high concentration of attention and speed of psychomotor reactions (including vehicle management and work with complex mechanisms).
OVERDOSE
Symptoms: depression of the central nervous system, nystagmus, ataxia, lowering of blood pressure, excitation, dizziness, weakness, chronic intoxication with bromine (depression, apathy, rhinitis, conjunctivitis, hemorrhagic diathesis, impaired coordination of movements).
Treatment: discontinuation of the drug, gastric lavage and symptomatic therapy, with CNS depression - caffeine, niketamide.
DRUG INTERACTION
Drugs that depress the central nervous system, enhance the effect of the drug.
Phenobarbital (inducer of microsomal oxidation) can reduce the effectiveness of drugs metabolized in the liver (including coumarin derivatives, griseofulvin, glucocorticosteroids, oral contraceptives); strengthens the action of local anesthetic, analgesic and hypnotics. The drug increases the toxicity of methotrexate.
The effect of the drug increases with the use of drugs valproic acid.
TERMS OF RELEASE FROM PHARMACY
The drug is approved for use as a means of OTC.
TERMS AND CONDITIONS OF STORAGE
In the dark place at a temperature of 15 В° C to 25 В° C. Keep out of the reach of children.
Shelf life - 2 years. Do not use after the expiry date printed on the package.
